Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dong-A Pharmaceutical, Meiji Seika Pharma Join For Biosimilar Distribution In Japan And Korea

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's leading pharma company Dong-A Pharmaceutical Co. will join the biosimilar sector, years behind its domestic competitors. The company signed a memorandum of understanding with the Korean authorities to build a biosimilar plant in collabration with Japan's Meiji Seika Pharma Co. Ltd. at the Songdo Free Economic Zone in Incheon City, about 10 miles west of Seoul

You may also be interested in...



Korea’s Dong-A Pharmaceutical Inks JV To Build Plant In Mongolia

Struggling from a recent indictment of over rebates, Korea’s leading pharma seeks new momentum in one of the most sparsely populated countries in the world.

Struggling From Price Cuts, Korea’s Dong-A Looks To Change Course

Korea’s top pharma company saw flat sales and a drop in profits in the third quarter, showing the impact of industry-wide price cuts. GSK holds a 10% stake in Dong-A.

Korea’s Anti-Rebate Task Force Raids Dong-A Pharmaceutical

A South Korean task force aimed at rooting out illegal drug rebates, raided the head office of top domestic drug company Dong-A in which GlaxoSmithKline and Otsuka Pharmaceutical hold stakes.

Related Content

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel